Is pyoderma gangrenosum associated with solid malignancies? Insights from a population‐based cohort study
Background The question of whether solid malignancies (SMs) are associated with pyoderma gangrenosum (PG) remains to be conclusively answered. Objective To evaluate the risk of SM among patients with PG and the odds of PG after a diagnosis of SM. Methods A population‐based retrospective cohort study...
Saved in:
Published in | Australasian journal of dermatology Vol. 62; no. 3; pp. 336 - 341 |
---|---|
Main Authors | , , , , |
Format | Journal Article |
Language | English |
Published |
Australia
Wiley Subscription Services, Inc
01.08.2021
|
Subjects | |
Online Access | Get full text |
Cover
Loading…
Summary: | Background
The question of whether solid malignancies (SMs) are associated with pyoderma gangrenosum (PG) remains to be conclusively answered.
Objective
To evaluate the risk of SM among patients with PG and the odds of PG after a diagnosis of SM.
Methods
A population‐based retrospective cohort study was conducted to study the risk for SM in patients with PG (n = 302) as compared with age‐, sex‐ and ethnicity‐matched control subjects (n = 1799). A case–control design was used to estimate the odds of PG in those with a preexisting history of SM.
Results
The prevalence of a preexisting SM was comparable in patients with PG and controls (7.5% vs. 8.8%, respectively; P = 0.490). The odds of having PG following a diagnosis of a SM was not statistically increased (OR, 0.85; 95% CI, 0.53–1.36). The incidence of SM was 6.8 (95% CI, 3.5–12.2) and 7.9 (95% CI, 6.1–10.1) per 1000 person‐years among patients with PG and controls, respectively. Patients with PG were not more likely to develop SM as compared to controls (HR, 0.86; 95% CI, 0.44–1.69). Patients with a dual diagnosis of PG and SM were older and had more frequent comorbid conditions and increased mortality.
Conclusions
SM is not associated with provoking PG, and patients with PG are not at an increased risk of developing SM. A thorough routine screening for SM in patients with new‐onset PG is an unnecessary approach based on the study findings. |
---|---|
Bibliography: | Equal contribution. Conflict of interest: ADC served as an advisor, investigator or speaker for AbbVie, BI, Dexcel Pharma, Janssen, Novartis, Perrigo, Pfizer and Rafa. None of the other authors have any conflicts of interest to declare. Khalaf Kridin, MD, PhD. Rimma Laufer Britva, M.D. Dana Tzur Bitan, PhD. Giovanni Damiani, MD. Arnon D. Cohen, MD, MPH, PhD. Funding sources: None. ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 content type line 23 |
ISSN: | 0004-8380 1440-0960 1440-0960 |
DOI: | 10.1111/ajd.13631 |